





NeoCore Technology Co., Ltd. Investor Conference

2024/12/25



DR. HPV Genotyping IVD KIT

- The DR. HPV Genotyping IVD kit can identify 27 genotypes, including 15 high-risk and 12 low-risk. In addition to the 27 genotypes, there is a HPV consensus probe stands for infection of any HPV.
- High-Risk : HPV 16 / 18 / 31 / 33 / 35 / 39 / 45 / 51 / 52 / 56 / 58 / 59 / 68 / 73 / 82
- Moderate/Low-risk : HPV 6 / 11 / 53 / 54 / 61 / 62 / 66 / 69 / 70 / 72 / 81 / 84





DR. HPV Genotyping IVD KIT

MOHW-MD-No. 004934



- **Specimens**
Cervical cell suspension


- **Product Characteristics**

Due to human papillomavirus (HPV) are more than 100 subtypes, and the persistent infection with high-risk human papillomavirus (HPV) is the main cause of cervical cancer. Human papillomavirus (HPV) DNA genotype detection can effectively increase the sensitivity of virus infection screening, and closely monitor the infection types. Through early detection of precancerous lesions and related treatment, the cure rate of cervical cancer can be improved. DR. HPV Genotyping IVD kit detects human papillomavirus (HPV) and discriminates between the different genotypes, thus providing physicians with detailed information on the nature of the infection. In order to provide a better acknowledgement for screening and tracing the HPV infected patients.



NeoCore's Recent Investment Case^(1/2)

- The company's Board meeting passed a resolution on December 17 to acquire 69% of the shares in VICTORY EIGHT ENTERPRISE CO., LTD. for a cash price of NT\$105 million.
- The VICTORY EIGHT ENTERPRISE CO., LTD., established in 1984, is a medical equipment sale agency company, primarily engaged in the agency sales of aesthetic medical equipment (such as laser instruments, ultrasound instruments, and beauty devices), equipment leasing, and providing technical support and warranty-related services.



LUTRONIC Genius



LUTRONIC Picoplus



LUTRONIC Clarity II



HIRONIC New Double



NeoCore's Recent Investment Case^(2/2)


- The market demand for aesthetic medicine in Taiwan continues to grow. Through this acquisition, our company not only enters the field of aesthetic medical equipment but also gains access to the medical system distribution relationships established by VICTORY EIGHT ENTERPRISE CO., LTD. over its 40 years of operation. This will help expand our other medical products and generates synergistic effects. It will also benefit our company's future strategic layout of medical products.
- In the future, our company will continue to strengthen overall operational management, enhance our ability to face external competitive environments, and improve shareholder equity.



Financial status and risk of NeoCore

NeoCore Technonoly is still at a loss state in recent years , so please investors should be prudent investment.

單位:仟元,每季(UNIT:THOUASND,QUARTER)






Financial status and risk of NeoCore

NeoCore Technonoly is still at a loss state in recent years , so please investors should be prudent investment.

2024 YEAR PRODUCT CATEGORY (UNIT:THOUASND)




- 子宮頸乳突病毒檢測套組(HPV KIT)
- 微生物檢驗試劑套組銷售(MIC KIT)
- 食安類檢測產品(FOOD KIT)
- 其他類(OTHER)
- 子公司隱型眼鏡營收(Subsidiary Operating revenue)



Financial status and risk of NeoCore

NeoCore Technonoly is still at a loss state in recent years , so please investors should be prudent investment.






Financial status and risk of NeoCore

NeoCore Technonoly is still at a loss state in recent years , so please investors should be prudent investment.

單位:仟元,每季(UNIT:THOUASND,QUARTER)



當期淨利(Net Income)	(4,998)	(14,812)	(11,646)	(14,929)	(12,029)	(20,124)	(23,410)	(27,093)	(18,741)	(17,930)	(15,783)
當期EPS(EPS)	(0.21)	(0.52)	(0.44)	(0.32)	(0.45)	(0.39)	(0.50)	(0.53)	(0.40)	(0.39)	(0.36)



Thank You